Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.
作者信息
Ricciuti Biagio, Wang Xinan, Awad Mark M
机构信息
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard School of Public Health, Boston, Massachusetts.
出版信息
JAMA Oncol. 2023 Apr 1;9(4):570-571. doi: 10.1001/jamaoncol.2022.7589.
Abstract
摘要
相似文献
1
Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.肿瘤突变负荷水平升高与非小细胞肺癌对程序性死亡受体1配体（PD-L1）阻断治疗的敏感性——回复
JAMA Oncol. 2023 Apr 1;9(4):570-571. doi: 10.1001/jamaoncol.2022.7589.
2
Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.非小细胞肺癌的肿瘤突变负荷水平增加及其对程序性死亡受体1配体（PD-L1）阻断的敏感性
JAMA Oncol. 2023 Apr 1;9(4):570. doi: 10.1001/jamaoncol.2022.7586.
3
Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.非小细胞肺癌的肿瘤突变负荷水平增加及其对程序性死亡受体1配体（PD-L1）阻断的敏感性
JAMA Oncol. 2023 Apr 1;9(4):569-570. doi: 10.1001/jamaoncol.2022.7583.
4
PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.PD-1/PD-L1 抑制剂治疗晚期非小细胞肺癌患者的 PD-L1 表达和 EGFR 状态：一项荟萃分析。
Future Oncol. 2019 May;15(14):1667-1678. doi: 10.2217/fon-2018-0639. Epub 2019 May 1.
5
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.程序性死亡配体 1 表达和肿瘤突变负担状态预测非小细胞肺癌对化疗和靶向治疗的反应。
J Exp Clin Cancer Res. 2019 May 14;38(1):193. doi: 10.1186/s13046-019-1192-1.
6
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.MET 外显子 14 改变的肺癌患者的 PD-L1 表达、肿瘤突变负担和免疫治疗反应。
Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.
7
[Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with
Non-small Cell Lung Cancer].[非小细胞肺癌患者肿瘤突变负荷异质性的研究进展]
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):293-298. doi: 10.3779/j.issn.1009-3419.2021.102.12.
8
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.通过靶向测序进行基因组评分，以确定免疫治疗的临床获益。
Eur J Cancer. 2019 Oct;120:65-74. doi: 10.1016/j.ejca.2019.08.001. Epub 2019 Sep 4.
9
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.表皮生长因子受体（EGFR）突变的非小细胞肺癌中程序性死亡配体1的表达及T790M状态
Lung Cancer. 2017 Sep;111:182-189. doi: 10.1016/j.lungcan.2017.07.022. Epub 2017 Jul 20.
10
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.程序性死亡配体 1 表达、肿瘤突变负荷和癌症基因突变是预测非小细胞肺癌免疫检查点阻断获益的更强指标，优于 HLA Ⅰ类基因分型。
J Thorac Oncol. 2019 Jun;14(6):1021-1031. doi: 10.1016/j.jtho.2019.02.008. Epub 2019 Feb 16.
本文引用的文献
1
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.非小细胞肺癌中高肿瘤突变负荷与 PD-L1 表达水平相关的免疫浸润增加和 PD-L1 阻断临床获益改善的相关性。
JAMA Oncol. 2022 Aug 1;8(8):1160-1168. doi: 10.1001/jamaoncol.2022.1981.
2
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.程序性细胞死亡配体 1（PD-L1）在非鳞状非小细胞肺癌中的表达与临床病理和基因组学相关性。
Ann Oncol. 2020 Jun;31(6):807-814. doi: 10.1016/j.annonc.2020.02.017. Epub 2020 Apr 27.
3
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.非小细胞肺癌同步放化疗后肿瘤 PD-L1 表达和肿瘤浸润性 CD8+T 淋巴细胞的变化。
Br J Cancer. 2019 Sep;121(6):490-496. doi: 10.1038/s41416-019-0541-3. Epub 2019 Aug 7.
4
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.非小细胞肺癌中 EGFR 突变亚型与免疫检查点阻断治疗的反应。
Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.
5
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.含铂化疗对非小细胞肺癌肿瘤细胞 PD-L1 表达的影响。
Cancer Res Treat. 2019 Jul;51(3):1086-1097. doi: 10.4143/crt.2018.537. Epub 2018 Nov 5.
6
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.一项评估帕博利珠单抗在 EGFR 突变、PD-L1 阳性、初治的晚期 NSCLC 患者中的疗效和安全性的 II 期临床研究。
J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1.
Zotero 插件